Your browser doesn't support javascript.
loading
Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy.
Zhou, Yangkai; Yuan, Jing; Xu, Ke; Li, Shilin; Liu, Ying.
Afiliação
  • Zhou Y; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
  • Yuan J; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Xu K; First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
  • Li S; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
  • Liu Y; University of Chinese Academy of Sciences, Beijing 100049, China.
ACS Nano ; 18(3): 1846-1864, 2024 Jan 23.
Article em En | MEDLINE | ID: mdl-38180952
ABSTRACT
Mutation burden, hypoxia, and immunoediting contribute to altered metabolic profiles in tumor cells, resulting in a tumor microenvironment (TME) characterized by accumulation of toxic metabolites and depletion of various nutrients, which significantly hinder the antitumor immunity via multiple mechanisms, hindering the efficacy of tumor immunotherapies. In-depth investigation of the mechanisms underlying these phenomena are vital for developing effective antitumor drugs and therapies, while the therapeutic effects of metabolism-targeting drugs are restricted by off-target toxicity toward effector immune cells and high dosage-mediated side effects. Nanotechnologies, which exhibit versatility and plasticity in targeted delivery and metabolism modulation, have been widely applied to boost tumor immunometabolic therapies via multiple strategies, including targeting of metabolic pathways. In this review, recent advances in understanding the roles of tumor cell metabolism in both immunoevasion and immunosuppression are reviewed, and nanotechnology-based metabolic reprogramming strategies for enhanced tumor immunotherapies are discussed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article